Tucatinib in Combination with Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, discusses updated results of the HER2CLIMB trial of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer.

EP. 1: Treatment Options in HER2-Positive Metastatic Breast Cancer

July 15th 2021

An overview of treatment options for HER2-positive metastatic breast cancer and practical guidance on selecting therapy.

EP. 2: Tucatinib for HER2-Positive Metastatic Breast Cancer

July 15th 2021

Efficacy of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer, including patients with brain metastases or visceral disease.

EP. 3: Updated Results from HER2CLIMB and Tucatinib Use in Patient Subgroups

July 15th 2021

Combination therapy with tucatinib, trastuzumab, and capecitabine shows efficacy in all patient populations studied.

EP. 4: Adverse Events in HER2-Positive Metastatic Breast Cancer Treatment

July 15th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with tucatinib, trastuzumab, and capecitabine based on safety data from HER2CLIMB.

EP. 5: Treatment Sequencing for HER2-Positive Metastatic Breast Cancer

July 15th 2021

Sara A. Hurvitz, MD, comments on her preferences for treating patients with HER2-positive metastatic breast cancer and shares her strategy for sequencing therapies.

EP. 6: Future Directions in HER2-Positive Metastatic Breast Cancer

July 15th 2021

Sara A. Hurvitz, MD, reviews therapy options for patients with HER2-positive metastatic breast cancer and comments on emerging therapeutic strategies.